“20 Heart Attacks”: 50 Times Doctors Were Left Speechless By A Patient’s Incorrect Self-Diagnosis
I’ve had a patient claim that amputations run in his family. He said that was the only reason…
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and…
Without Obamacare subsidies, this couple’s insurance premiums are set to go up almost $2,000
In late September, Laurel Vincenty got a letter from Blue Cross Blue Shield informing her that the subsidies…
AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs | US healthcare
Donald Trump announced a deal with the British-based drugmaker AstraZeneca for a “most-favored-nation” drug-pricing model aimed at making…
Trump’s Doctor Says Health ‘Exceptional’ After Walter Reed Visit
President Donald Trump underwent what his physician described as a “scheduled, follow-up evaluation” at Walter Reed Medical Center,…
How Are We Still Fighting About Obamacare?
This article was featured in the One Story to Read Today newsletter. Sign up for it here. Has…
TrumpRx Is a Narcissistic, AI-Generated Nightmare
Donald Trump, the convicted felon and current President of the United States, officially launched a new government website…
J&J Must Pay Record $966 Million in Talc Baby Powder Cancer Case
Johnson & Johnson was told by a California jury to pay $966 million to the family of a…
Scott Power: ASX health stocks lift in good news week across sector
The ASX’s healthcare sector made for good reading this week. Pic: Getty Images ASX health sector moved up…
A Look at OneMedNet (ONMD) Valuation Following Strategic Medcase Collaboration in Healthcare AI Data
OneMedNet (ONMD) is making headlines after announcing a strategic partnership with Medcase, a global leader in medical data…
Ozempic-Maker Novo Stops Work on Cell Therapy Cure for Type 1 Diabetes
Novo Nordisk A/S cut its cell therapy division, which has been trying to find a cure for type…
Pfizer’s Deal on Drug Prices Is Good But Deserves Scrutiny
American taxpayers spend billions of dollars annually supporting pharmaceutical development. Yet the US continues to pay more for…